Medtronic Plc (NYSE:MDT) reported fourth-quarter 2024 sales of $8.59 billion, beating the consensus of $8.44 billion. Revenue increased 0.5%, as reported, and 5.4% organic. The company’s organic revenue results reflect broad-based growth across the company, with mid-single-digit or higher organic revenue growth in all four segments.  The medical device maker reported adjusted EPS of $1.46, beating the consensus of $1.45. Related: Medtronic’s Latest Generation Of Transcatheter Aortic Valve Replacement Implant Passes FDA’s Muster, Shares Gain. Dividend: The company increased its quarterly dividend to $0.70 per share from $0.69. “Our momentum is building into the new fiscal year. ...